Skip to content

Investigating the efficacy and safety of Nivasha oral spray in controlling the symptoms of patients with COVID-19

Investigating the efficacy and safety of Nivasha oral spray in controlling the symptoms of patients with COVID-19

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20080901001165N59
Enrollment
80
Registered
2020-05-27
Start date
2020-05-25
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Covid-19

Interventions

Intervention 1: Intervention group: Nivasha spray 1 puff into the mouth every 6 hours, for 7 days (In addition to routine treatment according to the latest national guideline for the treatment of new

Sponsors

Nanoalvand arad company
Lead Sponsor
Bagheiat-allah University of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age: equal or more than 18 years; The patient have written consciously and freely consent to participate in the study. The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19. Confirmed diagnosis of COVID-19, with RT-PCR confirmation. Less than 7 days have passed since the onset of symptoms.

Exclusion criteria

Exclusion criteria: History of allergy to this spray ingredients; The patient is in another clinical trial at the same time; The patient needs to be hospitalized; Pregnancy; Lactation.

Design outcomes

Primary

MeasureTime frame
Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Rezapour

Bagheiat-allah University of Medical Sciences

drrezapourmh@gmail.com+98 21 8245 5393

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026